Gene-Driven Adjuvant Therapy for NSCLC Leads to Big Improvement in DFS

(MedPage Today) — CHICAGO — Biomarker-driven adjuvant therapy for intermediate/high-risk non-small cell lung cancer (NSCLC) led to significantly longer disease-free survival (DFS) as compared with observation, a randomized trial showed.
DFS…

Source link : https://www.medpagetoday.com/meetingcoverage/asco/115810

Author :

Publish date : 2025-05-31 12:00:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30	31

Gene-Driven Adjuvant Therapy for NSCLC Leads to Big Improvement in DFS

The Covid Inquiry Podcast: ‘I wasn’t the decision maker’

Sacituzumab or Chemo in First-Line TNBC: Which Is Better?

Related Posts

Key Drivers of High Costs in Head and Neck Cancer Care

Ancient ‘terror birds’ may have been no match for hungry giant caimans

‘Ozempic Teeth:’ Another Effect of GLP-1 Agonists?

Yes, HCQ Does Help Preserve Renal Function in Lupus Nephritis

Pentagon Tightens Rules on Getting Medical Waivers to Join the Military

Multidrug Regimen Appears Feasible for Older Patients With Advanced Hodgkin Lymphoma

Key Drivers of High Costs in Head and Neck Cancer Care

Ancient ‘terror birds’ may have been no match for hungry giant caimans

‘Ozempic Teeth:’ Another Effect of GLP-1 Agonists?

Yes, HCQ Does Help Preserve Renal Function in Lupus Nephritis

Pentagon Tightens Rules on Getting Medical Waivers to Join the Military

Multidrug Regimen Appears Feasible for Older Patients With Advanced Hodgkin Lymphoma

Cleaner air has increased the number of city heatwaves

CGM Receiver Recall; Interchangeable Novolog Biosimilar OK’d; Barbie With Diabetes

Categories

Archives